OXFORD, England, November 18 ProImmune Ltd, a leadingprovider of quality research reagents for monitoring the immune system andepitope discovery, has today announced the introduction of the REVEAL(TM)Immunogenicity System. This comprehensive suite of services helps to designand select biological drug leads at the preclinical stage, thereby minimizingthe risk of adverse drug reactions related to unwanted immunogenicity.
The immunogenicity of biological drugs can often be a significantobstacle in the development of successful new therapies. Unwantedimmunogenicity can manifest itself particularly through anti-drug antibody(ADA) responses. These responses can lead to allergic reactions, reduction orneutralization of the activity of the drug and, in some cases, cross-reactiveimmune responses, which could lead to serious adverse events.
ProImmune's new REVEAL(TM) Immunogenicity System combines, for the firsttime, cell-free HLA-peptide binding assays for more than 50 class II HLAalleles, with highly sensitive T cell proliferation assays. This combinationenables the creation of a detailed profile of the helper T cell immuneresponse to one or more drug leads. The role of helper T cells is known to beof critical importance in controlling unwanted anti-drug antibody responses.If desired, the leads analyzed can then be re-engineered to remove unwantedhelper T cell epitopes and produce a re-validated drug lead with improvedimmunogenicity risk.
Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our experienced scientistshave brought together an unrivalled range of physical class II HLA bindingassays and sensitive T cell assays for predicting immunogenicity risk. TheREVEAL(TM) System sets a new paradigm for immunogenicity risk management atthe pre-clinical stage. It is a natural evolution of ProImmune's leadingtechnology platforms in T cell immunology."
ProImmune provides the REVEAL(TM) Immunogenicity System as a highlycustomizable service, purely on a 'fee for service' basis.
Notes to Editors:
About ProImmune - http://www.proimmune.com
ProImmune is a private biotechnology company with its headquarters inOxford, UK, that specializes in providing products and services for epitopediscovery, immune monitoring and the design of biological drugs with reducedimmunogenicity risk. ProImmune has a wide range of customers from leadingpharmaceutical and biotechnology companies, as well as clinical and academicresearch institutes throughout the world.
SOURCE ProImmune Ltd